Early Access — free while we kick the tires
EdgarHawk

Jung Melita Sun

Chief Business Officer

Officer
1 filing analyzed · 1 company · Latest 2025-02-03

Companies

Company Buys Sells Direction
Terns Pharmaceuticals, Inc. TERN 1 0 Net buying

Activity

February 2025
medium
Buy
2,250 shares
$11,498
Significance 4/10

CBP Jung Melita Sun buys 2,250 shares of TERN at $5.11 amid -100.0% revenue decline and $-21.9M net loss.

Jung Melita Sun, as Chief Business Officer, purchased 2,250 shares at $5.11 on 2024-11-30, establishing an initial open-market position in TERN. The company faces severe financial headwinds: full-year revenue declined -100.0% year-over-year and net income totaled $-21.9M, indicating the company is unprofitable. The stock has declined significantly from its 52-week high, trading at $4.37 (down 30-day: -24.0%, 90-day: -39.0%). This insider purchase from a C-suite executive occurs within a context of material deterioration in the company's financial performance and substantial stock weakness, warranting attention to whether this reflects management's forward-looking perspective on business trajectory.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access